Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Rothenhäusler, HB.
Clinical features, diagnosis and treatment of HIV-induced neuropsychiatric disorders
Wien Med Wochenschr. 2006; 156(23-24): 644-656.
Doi: 10.1007/s10354-006-0353-y
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
Rothenhäusler Hans-Bernd
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Since the acquired immune deficiency syndrome (AIDS) was first recognized in 1981, more than 25 million individuals have died from complications of the human immunodeficiency virus (HIV) infection. The introduction of highly active antiretroviral therapy (HAART) in 1995 has resulted in a significantly decreased incidence rate of AIDS in the developed world. As HAART led to considerable improvements in survival for patients with HIV infection, HIV-neurotropically associated neuropsychiatric disorders have become an increasingly important challenge for clinical medicine. This article gives an overview of epidemiology, clinical features, diagnosis, and therapy of HIV-induced cognitive-motor impairments including HIV-associated dementia complex, organic mood disorders and psychosis.
- Find related publications in this database (using NLM MeSH Indexing)
-
AIDS Dementia Complex - classification
-
Acquired Immunodeficiency Syndrome - complications
-
Anti-HIV Agents - therapeutic use
-
Antiretroviral Therapy, Highly Active - therapeutic use
-
Case-Control Studies - therapeutic use
-
Cognition Disorders - drug therapy
-
Cohort Studies - drug therapy
-
Depression - drug therapy
-
Diagnosis, Differential - drug therapy
-
Electroencephalography - drug therapy
-
Female - drug therapy
-
HIV Infections - complications
-
Humans - complications
-
Incidence - complications
-
Male - complications
-
Mental Disorders - chemically induced
-
Mood Disorders - drug therapy
-
Peripheral Nervous System Diseases - diagnosis
-
Prevalence - diagnosis
-
Prospective Studies - diagnosis
-
Psychotropic Drugs - adverse effects
-
Reverse Transcriptase Inhibitors - therapeutic use
-
Risk Factors - therapeutic use